

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

FEB 21 2002

TECH CENTER 1600/2900



CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

January 9, 2002
Date

Steven L. Highlander

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

David J. MANGELSDORF *et al.*

Serial No.: 09/460,292

Group Art Unit: 1615

Filed: December 10, 1999

Examiner: J. Woitach

For: COMPOSITIONS AND METHODS OF
MODULATING CHOLESTEROL
METABOLISM

Atty. Dkt. No.: UTSD:596/SLH

DECLARATION UNDER 37 C.F.R. § 1.48(a)

Commissioner for Patents
Washington, D.C. 20231


We, the undersigned, do declare that:

1. We are named inventors for the above-captioned application.
2. We are authors of Peet *et al.*, *Cell* 93:693-704 (1998).
3. Daniel J. Peet and Jean-Marc A. Lobaccaro were named as authors on the Peet *et al.* papers but were not named as inventors on the instant application.

4. In reviewing the subject matter presently being examined, it has become apparent to us that the inventorship of the instant application should be corrected to add both Daniel J. Peet and Jean-Marc A. Lobaccaro.
5. Daniel J. Peet performed the experiments that generated the LXRx-knockout mice. He also performed the experiments that demonstrated the phenotype of these mice and the unequivocal role of LXR in cholesterol metabolism.
6. Jean-Marc A. Lobaccaro conducted experiments together with Dr. Peet to demonstrate the phenotype of the LXRx-knockout mice, and to establish the role of LXR as a therapeutic target for modulating cholesterol metabolism.
7. In light of these substantial contributions, it is our opinion that both Peet and Lobaccaro contributed substantially to the rationale and design of the studies reported in the Peet *et al.* paper, and claimed in the instant application. Their omission as inventors from the original application was made without deceptive intent.


8. We hereby declare that all statements made herein of our knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

12/17/01
Date




David J. Mangelsdorf, Ph.D.

12/17/01
Date



Stephen D. Turley, Ph.D.

12-17-01
Date



John Dietschy, Ph.D.